MedinCell S.A.
MEDCL.PA · PAR
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.57 | -0.04 | 0.09 |
| FCF Yield | 0.00% | 4.68% | -0.12% | -7.58% |
| EV / EBITDA | 0.00 | -66.71 | -27.81 | -63.63 |
| Quality | ||||
| ROIC | 0.00% | -22.51% | -45.26% | -21.77% |
| Gross Margin | 0.00% | 100.00% | 91.26% | 58.55% |
| Cash Conversion Ratio | 0.89 | 0.74 | -1.48 | 0.01 |
| Growth | ||||
| Revenue 3-Year CAGR | 56.45% | 48.70% | 42.88% | 44.09% |
| Free Cash Flow Growth | 0.00% | 6,477.31% | 97.52% | -25.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -3.85 | -3.42 | -14.27 |
| Interest Coverage | 0.00 | -4.24 | -2.70 | -4.24 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.40 | 0.00 |
| Cash Conversion Cycle | 0.00 | 27.44 | -224.69 | -35.28 |